Heptamidine is a potent inhibitor of the calcium-binding protein S100B (Kd = 6.9 μM), selectively killing S100B-expressing melanoma cells; it is a valuable tool for studying myotonic dystrophy (DM). In vitro, Heptamidine rescues mis-splicing of minigene reporters in a HeLa cell DM1 model with an EC50 of 15 μM. In vivo, it reverses splicing defects and rescues myotonia in a DM mouse model, reducing exon 7a inclusion to wild-type levels (6±1%) and decreasing myotonia from grade 3 to grade 1 or 0 at doses of 20 or 30 mg/kg (intraperitoneal injection, once daily for 7 days).